Survival-focused adventure ExeKiller looks like a Blade Runner immersive sim, and those four words in that order make me very ...

Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best up and coming stocks with huge upside potential. On August 28, BofA analyst Tim Anderson raised the firm’s price target on Apogee Therapeutics ...

SAN FRANCISCO and BOSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for ...

Julio is a Senior Author for Collider. He studied History and International Relations at university, but found his calling in cultural journalism. When he isn't writing, Julio also teaches English at ...

APEX Part A met all primary and key secondary endpoints and exceeded trial objectives, including 71.0% decrease from baseline in EASI at Week 16 APG777 demonstrated EASI-75 of 66.9% (42.5% ...

(RTTNews) - Apogee Therapeutics, Inc. (APGE) announced positive 16-week data from Part A of the Phase 2 APEX clinical trial of APG777, a potential anti-IL-13 antibody, in patients with ...

Apogee Therapeutics Inc. plans to enter a crowded atopic dermatitis market with established drugs, such as Dupixent (dupilumab, Regeneron Pharmaceuticals Inc. and Sanofi SA) and Ebglyss ...

New York, New York--(Newsfile Corp. - June 24, 2025) - Apex Group Ltd. ("Apex Group" or "the Group"), the leading global financial services provider, announces the appointment of Jeff Weiner as Chief ...

Israel’s Ministry of Health (MoH) approval to add additional sites to APEX SUMMIT-90 160 patient phase 2b macrodose clinical trial: Tel Aviv University (TAU)’s Institute for Psychedelic Research ...

Marathons have a unique way of bringing out the best in humanity. And this special caught-on-camera moment from the Boston Marathon was no exception. Lucia R. Kempton was standing near the finish line ...

Guselkumab, an IL-23 inhibitor, is effective in reducing signs, symptoms, and structural damage in active PsA, as confirmed by the APEX study. The FDA approved guselkumab in 2020 based on DISCOVER ...

Johnson & Johnson (NYSE:JNJ) on Friday announced topline results from Phase 3b APEX study of Tremfya (guselkumab) in patients with active psoriatic arthritis (PsA) who are biologic naïve and have had ...